×
About 1,095 results

ALLMedicine™ Branch Retinal Vein Occlusion Center

Research & Reviews  351 results

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
https://clinicaltrials.gov/ct2/show/NCT04137120

Jun 22nd, 2022 - The primary objective is to assess the safety of intravitreal aflibercept injections in patients with wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), macular edema secondary to...

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT04740905

Jun 15th, 2022 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Optical coherence tomography angiography as predictor of visual outcomes in retinal vei...
https://doi.org/10.1177/11206721221099487
European Journal of Ophthalmology; Mejía ME, Ríos HA et. al.

May 6th, 2022 - Evaluate optical coherence tomography angiography (OCT-A) features in retinal vein occlusions (RVO) associated with visual outcomes after anti-VEGF. Analytical observational study performed in eyes with macular edema secondary to RVO treated with ...

Navigated Laser In Branch Retinal Vein Occlusion Study
https://clinicaltrials.gov/ct2/show/NCT03651011

Apr 20th, 2022 - Purpose of the study In a 12-month prospective, randomized 1:1 study of patients with branch retinal vein occlusion (BRVO) and macular edema, the investigators aim to Examine the treatment response of patients treated with intravitreal aflibercept...

Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects
https://clinicaltrials.gov/ct2/show/NCT01746615

Apr 7th, 2022 - Assessment of retinal vessel calibers combined with bidirectional Fourier domain optical coherence tomography (FDOCT) for measurement of retinal blood velocities is a new and sophisticated method for assessing retinal blood flow in humans. The val...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  64 results

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
https://clinicaltrials.gov/ct2/show/NCT04137120

Jun 22nd, 2022 - The primary objective is to assess the safety of intravitreal aflibercept injections in patients with wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), macular edema secondary to...

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT04740905

Jun 15th, 2022 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Navigated Laser In Branch Retinal Vein Occlusion Study
https://clinicaltrials.gov/ct2/show/NCT03651011

Apr 20th, 2022 - Purpose of the study In a 12-month prospective, randomized 1:1 study of patients with branch retinal vein occlusion (BRVO) and macular edema, the investigators aim to Examine the treatment response of patients treated with intravitreal aflibercept...

Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects
https://clinicaltrials.gov/ct2/show/NCT01746615

Apr 7th, 2022 - Assessment of retinal vessel calibers combined with bidirectional Fourier domain optical coherence tomography (FDOCT) for measurement of retinal blood velocities is a new and sophisticated method for assessing retinal blood flow in humans. The val...

Minocycline to Treat Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT01468831

Jan 26th, 2022 - Objective: Retinal vein occlusions (RVO) are significant sources of vision loss, affecting mostly healthy people over 55 years of age. The common source of vision loss is the macular edema accompanying the retinal injury. Very recently, studies em...

see more →

News  22 results

Aflibercept Superior to Photocoagulation for Macular Edema?
https://www.medscape.com/viewarticle/840759

Mar 5th, 2015 - Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study Campochiaro PA, Clark WL, Boyer DS, et al Ophthalmology. 2015;122:538-544 Study Summary The VIBRANT study was a 24-week, d...

Two Ophthalmic Drugs Receive Positive Nods in Europe
https://www.medscape.com/viewarticle/838649

Jan 23rd, 2015 - The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of ciclosporin eye drops (Ikervis, Santen SAS) for the treatment of severe keratitis in adults with dry eye disease. The 1 mg/mL ciclosporin dr...

Visual Gains With Aflibercept Upheld at 52 Weeks in VIBRANT
https://www.medscape.com/viewarticle/836129

Dec 8th, 2014 - CHICAGO — For patients with macular edema related to branch retinal vein occlusion, monthly intravitreal aflibercept (Eylea, Regeneron) injections can lead to visual gains at 24 weeks that are maintained at 52 weeks, report investigators from the ...

FDA OKs Aflibercept (Eylea) for Diabetic Macular Edema
https://www.medscape.com/viewarticle/829136

Jul 30th, 2014 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron Pharmaceuticals) injection solution to treat visual impairment caused by diabetic macular edema (DME), the manufacturer announced yesterday. The new indication fo...

EU Panel Endorses Use of 2 Diabetes-Related Products
https://www.medscape.com/viewarticle/828930

Jul 25th, 2014 - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued 2 new positive opinions for products related to the treatment of patients with diabetes. The CHMP recommended granting market authorization...

see more →